ScholarLens Back to search
1994•The Chinese Journal of Clinical PharmacologyRequires access

A RANDOMIZED CONTROLLED CLINICAL TRIAL OF AZITHROMYCIN IN THE TREATMENT OF BACTERIAL INFECTIONS

Had Feng

Open publisher page 0 citations

Abstract

Azithromycin is a new azalide antibiotic. A randomized controlled clinical trial wasconducted to evaluate the efficacy and safety of azithromycin in comparison with roxithromycin in the treatment of 60 cases of bacterial infection. 30 patients were administered azithromycin once daily at the dosage of 500 mg on day 1 and 250 mg on day 2-5 each, The other 30 patients received roxithromycin at 300 mg bid on day 1 and 150 mg bid on day 2 - 5 each. So, the duration of treatment of either group was 5 days. The results showed that the overall clinical efficacy rates of azithromycin and roxithromycin were 93.3% and 90.0% respectively, and the bacterial clearance rates were 93.3% and 86.7% respectively. The incidence of adverse drug reaction of both groups was 10. 0% . These results indicated that there was no statistical difference in the clinical efficacy, bacterial clearance and adverse drug reaction between the two groups.

About this research paper

What this paper is about

Azithromycin is a new azalide antibiotic. A randomized controlled clinical trial wasconducted to evaluate the efficacy and safety of azithromycin in comparison with roxithromycin in the treatment of 60 cases of bacterial infection. 30 patients were administered azithromycin once daily at the dosage of 500 mg on day 1 and 250 mg on day 2-5 each, The other 30 patients received roxithromycin at 300 mg bid on day 1 and 150 mg bid on day 2 - 5 each. So, the duration of treatment of either group was 5 days. The results showed that the overall clinical efficacy rates of azithromycin and roxithromycin were 93.3% and 90.0% respectively, and the bacterial clearance rates were 93.3% and 86.7% respectively. The incidence of adverse drug reaction of both groups was 10. 0% . These results indicated that there was no statistical difference in the clinical efficacy, bacterial clearance and adverse drug reaction between the two groups.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Azithromycin is a new azalide antibiotic. A randomized controlled clinical trial wasconducted to evaluate the efficacy and safety of azithromycin in comparison with roxithromycin in the treatment of 60 cases of bacterial infection. 30 patients were administered azithromycin once daily at the dosage of 500 mg on day 1 and 250 mg on day 2-5 each, The other 30 patients received roxithromycin at 300 mg bid on day 1 and 150 mg bid on day 2 - 5 each. So, the duration of treatment of either group was 5 days. The results showed that the overall clinical efficacy rates of azithromycin and roxithromycin were 93.3% and 90.0% respectively, and the bacterial clearance rates were 93.3% and 86.7% respectively. The incidence of adverse drug reaction of both groups was 10. 0% . These results indicated that there was no statistical difference in the clinical efficacy, bacterial clearance and adverse drug reaction between the two groups.

Key concepts: Roxithromycin, Azithromycin, Medicine, Adverse effect, Randomized controlled trial, Antibiotics, Clinical trial, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
A RANDOMIZED CONTROLLED CLINICAL TRIAL OF AZITHROMYCIN IN THE TREATMENT OF BACTERIAL INFECTIONS — Research Paper | ScholarLens